APAC Antimicrobial Susceptibility Testing Market

APAC Antimicrobial Susceptibility Testing Market Size (2022 to 2027)

The size of the APAC region's antimicrobial susceptibility testing market is expected to grow at a CAGR of 8.37% from 2022 to 2027 and worth USD 1.44 billion by 2027 from USD 0.96 billion in 2022.

The high frequency of infectious diseases and raising awareness about early diagnosis are primarily driving the market forward in this region. Antibacterial medications serve an essential role in preventing infectious diseases; yet, antibiotic misuse and overuse have resulted in drug resistance. Controlling the spread of infectious diseases is difficult due to delays in detecting dangerous bacteria. This puts pressure on the key actors to provide test kits that provide accurate and effective results to be treated more effectively.

Increased use of antimicrobial susceptibility testing by biopharmaceutical, biotechnological, and pharmaceutical companies is a significant factor for the substantial growth in the antimicrobial susceptibility testing market in APAC, owing to an increasing focus on drug research, the advent of new diseases, as well as the rising prevalence of chronic diseases and antimicrobial resistance (AMR).

Automated antimicrobial susceptibility testing tools are expensive because they have many advanced features and functionalities. Incubation and detection times are reduced when automated AST methods are used. The expensive cost of these systems, on the other hand, is a significant impediment to their widespread adoption by end-users, particularly by small-budget institutions. Additionally, the lack of clinical breakpoints for many medicines limits the use of AST products.

This research report on the APAC antimicrobial susceptibility testing market has been segmented and sub-segmented into the following categories.

By Product:

• Manual Antimicrobial Susceptibility Testing Products
  • Susceptibility Testing Disks
  • MIC Strips
  • Susceptibility Testing Plates
• Automated Laboratory Instruments
• Culture and Growth Media
• Consumables

 By Application:

• Clinical Diagnostics
• Drug Discovery and Development
• Epidemiology

By End-User:

• Hospitals and Diagnostic Centers
• Pharmaceutical and Biotechnology Companies
• Research &Academic Institutes
• Clinical Research Organizations

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Geographically, Asia Pacific is one of the fastest developing regions in terms of growth across the globe, and China and India are expected to have a significant impact on the forecast period, as they held the bulk of the Asia Pacific antimicrobial susceptibility testing market share in 2020. Governments in countries such as China and India are putting a lot of emphasis on antimicrobial resistance policies and plans. Furthermore, activities to raise antimicrobial resistance knowledge and prevent antimicrobial abuse assist in teaching decision-makers, regulatory agencies, and other end users about antimicrobial resistance prevention. The rapid spread of multidrug-resistant microbial pathogens in countries such as China, India, and Japan have necessitated a thorough understanding of microbial infection mechanisms and the development of novel diagnostic tools and antimicrobials. The judicious use of broad-spectrum antimicrobial medications requires developing a fast and sensitive detection system that can quickly determine which drug is most effective against a given bacteria.

KEY MARKET PLAYERS:

Companies playing a notable role in the APAC antimicrobial susceptibility testing market profiled in this report are Danaher Corporation, Becton, Dickinson, and Company., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., HiMedia Laboratories Pvt. Ltd., Merlin Diagnostika GmbH, bioMerieux S.A., Merck KGaA, Accelerate Diagnostics, Inc., and Creative Diagnostics.